Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Gynecologic Oncology, 2(147), p. 267-275, 2017

DOI: 10.1016/j.ygyno.2017.08.022

Links

Tools

Export citation

Search in Google Scholar

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Journal article published in 2017 by Amit M. Oza, Anna V. Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A. McNeish, Elizabeth M. Swisher, Isabelle Ray-Coquard, Katherine Bell-Mcguinn, Robert L. Coleman, David M. O'Malley, Alexandra Leary, Lee-May Chen, Diane Provencher, Ling Ma, James D. Brenton and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO